All In Biotech

Drug Trial Radar · NCT04163991

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients With Rheumatoid Arthritis (RA)

Last checked: Nov 19, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

78

Actual

Start

Dec 9, 2019

Primary completion

Dec 28, 2021

Study completion Dec 28, 2021

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Nov 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of VIB4920 (formerly MEDI4920) in adult participants with rheumatoid arthritis (RA).

Conditions

  • Rheumatoid Arthritis

Interventions

  • VIB4920Drug

    liquid for IV infusion following dilution in normal saline

  • PlaceboDrug

    0.9% saline for IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Day 113 in DAS28-CRPTime frame: Day 1 (Baseline), Day 113
  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (TEAESIs)Time frame: From first dose of study drug through Day 309 ± 7 days

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Anniston, Alabama

  • Research Site

    Sun City, Arizona

  • Research Site

    Upland, California

  • Research Site

    Clearwater, Florida

  • Research Site

    Margate, Florida

  • Research Site

    Miami Lakes, Florida

  • Research Site

    Zephyrhills, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Lexington, Kentucky

  • Research Site

    Wheaton, Maryland

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Rocky Mount, North Carolina

  • Research Site

    Salisbury, North Carolina

  • Research Site

    Vandalia, Ohio

  • Research Site

    Norman, Oklahoma

  • Research Site

    Duncansville, Pennsylvania

  • Research Site

    Baytown, Texas

  • Research Site

    Dallas, Texas

  • Research Site

    Warsaw, Poland

  • Research Site

    Poznan, Greater Poland Voivodeship, Poland

  • Research Site

    Krakow, Lesser Poland Voivodeship, Poland

  • Research Site

    Nadarzyn, Masovian Voivodeship, Poland

  • Research Site

    Siedlce, Masovian Voivodeship, Poland

  • Research Site

    Bialystok, Podlaskie Voivodeship, Poland

  • Research Site

    Elblag, Warmian-Masurian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.